3. Discussion
peg-GCSF
This study is a prospective randomized phase III study to verify the hypothesis that same-day administration of pegteograstim is non-inferior to next-day administration for 3 to 5 day chemotherapy regimens in which intensively myelosuppressive chemotherapy agents are administered on day 1. If the same-day method is non-inferior in regard to efficacy, patient convenience can be improved by removing the need for extension of hospitalization or revisit hospital to meet the next-day injection schedule.The timing of administration of peg-GCSF is usually recommended to be 24 to 72 hours after completion of chemotherapy.However, although the ASCO guidelines stipulate administration after 24 hours, these guidelines also recommend the same-day method for patients who have difficulties with next-day peg-GCSF administration.We are now recruiting participants and the baseline database will be completed by 2023. Depending on the results, this study can officially promote the same-day administration of pegteograstim. This method has been unofficially applied on day 1 based on the results of retrospective studies or subgroup analyses of multi-day chemotherapy regimens that include administration of intensively myelosuppressive agents on the first day of chemotherapy.